DexCom, Inc. (NASDAQ:DXCM – Get Free Report) EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Jon Brown also recently made the following trade(s):
- On Friday, May 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00.
- On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00.
DexCom Trading Up 1.7%
DXCM opened at $72.47 on Friday. The firm’s fifty day moving average is $66.93 and its two-hundred day moving average is $67.88. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm has a market cap of $27.96 billion, a PE ratio of 30.97, a price-to-earnings-growth ratio of 1.11 and a beta of 1.45. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98.
Hedge Funds Weigh In On DexCom
Large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC boosted its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the period. Empowered Funds LLC boosted its position in shares of DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares during the period. Focus Partners Wealth grew its holdings in shares of DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after buying an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after buying an additional 258 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.
Analyst Ratings Changes
DXCM has been the topic of several recent analyst reports. Stifel Nicolaus set a $90.00 target price on DexCom and gave the stock a “buy” rating in a report on Friday, June 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a research report on Monday, June 1st. Benchmark started coverage on DexCom in a report on Monday, May 11th. They set a “buy” rating and a $77.00 price objective on the stock. Citigroup reiterated a “buy” rating and issued a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Finally, William Blair raised DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $84.83.
Check Out Our Latest Report on DexCom
About DexCom
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
See Also
- Five stocks we like better than DexCom
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
